WESTBROOK, Maine / May 10, 2023 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Stifel Jaws & Paws Conference on Wednesday, May 31, 2023. Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at 1:15 pm (EDT).
Individuals can access the live audio webcast of the presentation through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will be available via the same link.
2023 Investor Day
IDEXX Laboratories, Inc. also announced today that it will host its 2023 Investor Day on Thursday, August 10, 2023 at its corporate headquarters in Westbrook, Maine from approximately 8:00 am to 12:00 pm (EDT). A live webcast of the presentations will be available on www.idexx.com/investors. Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact This email address is being protected from spambots. You need JavaScript enabled to view it.. Additional information on IDEXX’s Investor Day will be provided closer to the date of the event.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs nearly 11,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit www.idexx.com.
Last Trade: | US$404.02 |
Daily Change: | -0.63 -0.16 |
Daily Volume: | 931,250 |
Market Cap: | US$33.080B |
February 03, 2025 October 31, 2024 August 21, 2024 August 06, 2024 June 04, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load